After Real-World Data Row, AZ Looks To NHS England For Tagrisso Deal
NICE Rejected Real World Data
Executive Summary
Tagrisso has become AstraZeneca’s oncology flagship product, but cannot secure frontline use in England.
Topics
- Subjects
- Commercial
- Government Payers
- Market Access
- Real-World Evidence
- Regions
- Europe
- Therapy Areas
- Cancer
- Industries
- BioPharmaceutical
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SC141529
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.
All fields are required.
SC141529
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.